293
views
0
recommends
+1 Recommend
0 collections
    12
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Purpose

          Following two cases of neutralizing antibodies to epoetin alfa in an investigational clinical study, a small number of individual syringes of two drug product batches were found to contain unusually high levels of aggregation at the end of the clinical trial.

          Methods

          We undertook an extensive analytical approach to determine the root-cause of the increased aggregation in the affected batches.

          Results

          Soluble tungsten was found in the syringes, most likely derived from the pins used to manufacture the syringes. Spiking of epoetin alfa with sodium polytungstate or an extract of tungsten pins used to manufacture the syringes induced the formation of aggregates, both dimers that appeared to be covalently linked by disulphide bonds as well as higher-order aggregates. Sodium polytungstate had also a strong denaturing effect on the protein.

          Conclusions

          We propose tungsten-mediated unfolding and aggregation of epoetin alfa in pre-filled syringes as a potential root cause for increased immunogenicity. This finding may be more broadly applicable to this and other classes of therapeutic proteins.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development

          ABSTRACT Within the European Immunogenicity Platform (EIP) (http://www.e-i-p.eu), the Protein Characterization Subcommittee (EIP-PCS) has been established to discuss and exchange experience of protein characterization in relation to unwanted immunogenicity. In this commentary, we, as representatives of EIP-PCS, review the current state of methods for analysis of protein aggregates. Moreover, we elaborate on why these methods should be used during product development and make recommendations to the biotech community with regard to strategies for their application during the development of protein therapeutics.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pure red-cell aplasia and epoetin therapy.

              Between 1988 and 1998, antibody-associated pure red-cell aplasia was reported in three patients who had undergone treatment with recombinant human erythropoietin (epoetin). Between 1998 and 2000, 13 such cases were reported from France--12 in patients who had received the Eprex formulation of epoetin alfa and 1 in a patient who had received Neorecormon (a formulation of epoetin beta); both are products that are marketed outside the United States. We obtained reports of epoetin-associated pure red-cell aplasia from the Food and Drug Administration and from the manufacturers of Eprex, Epogen (another formulation of epoetin alfa), and Neorecormon. The numbers of case reports and estimates of exposure-adjusted incidence were analyzed according to the product, the cause of anemia, the route of administration, the country in which pure red-cell aplasia was identified, and the date on which pure red-cell aplasia was reported. Between January 1998 and April 2004, 175 cases of epoetin-associated pure red-cell aplasia were reported for Eprex, 11 cases for Neorecormon, and 5 cases for Epogen. Over half these cases had occurred in France, Canada, the United Kingdom, and Spain. Between 2001 and 2003, the estimated exposure-adjusted incidence was 18 cases per 100,000 patient-years for the Eprex formulation without human serum albumin, 6 per 100,000 patient-years for the Eprex formulation with human serum albumin, 1 case per 100,000 patient-years for Neorecormon, and 0.2 case per 100,000 patient-years for Epogen. After procedures were adopted to ensure appropriate storage, handling, and administration of Eprex to patients with chronic kidney disease, the exposure-adjusted incidence decreased by 83 percent worldwide. After the peak incidence of Eprex-associated pure red-cell aplasia was reached in 2001, interventions designed in response to drug-monitoring programs worldwide resulted in a reduction of more than 80 percent in the incidence of pure red-cell aplasia due to Eprex. Copyright 2004 Massachusetts Medical Society
                Bookmark

                Author and article information

                Contributors
                +49-89613670138 , +49-89613670147 , andreas.seidl@sandoz.com
                Journal
                Pharm Res
                Pharm. Res
                Pharmaceutical Research
                Springer US (Boston )
                0724-8741
                1573-904X
                18 November 2011
                18 November 2011
                June 2012
                : 29
                : 6
                : 1454-1467
                Affiliations
                [1 ]Sandoz Biopharmaceuticals, Hexal AG, Keltenring 1 + 3, 82041 Oberhaching, Germany
                [2 ]Sandoz Biopharmaceuticals, Sandoz GmbH, Kundl, Austria
                [3 ]Hôpital Saint Antoine, Paris, France
                [4 ]Manhes Hospital, Fleury-Mérogis, France
                [5 ]King’s College Hospital, London, UK
                Article
                621
                10.1007/s11095-011-0621-4
                3349029
                22094831
                53f9a235-2b6e-4832-8d06-0af4c18af043
                © The Author(s) 2011
                History
                : 1 August 2011
                : 26 October 2011
                Categories
                Research Paper
                Custom metadata
                © Springer Science+Business Media, LLC 2012

                Pharmacology & Pharmaceutical medicine
                aggregation,tungsten,epoetin
                Pharmacology & Pharmaceutical medicine
                aggregation, tungsten, epoetin

                Comments

                Comment on this article